A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06712628

Acronym

UP-RISING

Enrollment

678

Registered

2024-12-02

Start date

2024-11-07

Completion date

2028-12-01

Last updated

2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Rheumatoid Arthritis

Keywords

Moderate to Severe Rheumatoid Arthritis, Rheumatoid Arthritis, Upadacitinib, Tumor Necrosis Factor Inhibitor Treatment

Brief summary

This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany. Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician. * Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study * UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies

Exclusion criteria

* Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug \[whichever is longer\] prior to baseline) * Prior treatment with Upadacitinib * Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study

Design outcomes

Primary

Measure	Time frame	Description
Retention Rate of UPA vs TNFi	Up to approximately 24 months	Time to the discontinuation of Upadacitinib. Time to the discontinuation of Tumor Necrosis Factor Inhibitor treatment

Countries

Germany

Contacts

CONTACTMedical Information Germany

medinfo.germany@abbvie.com49 611 1720 1520

STUDY_DIRECTORABBVIE INC.

AbbVie

Outcome results